低分子量肝素市場：依藥物、包裝、應用、最終用戶和地區分類

預計2026年，低分子量肝素市場規模將達50.739億美元，2033年將達到80.08億美元。預計從2026年到2033年，其複合年成長率將達到6.7%。

低分子肝素（LMWH）是一種藥理抗凝血劑，由未分級肝素（UFH）經化學或酵素解聚製成，其分子大小約為肝素的三分之一。低分子肝素用於預防深層靜脈栓塞症和肺動脈栓塞，並廣泛用於治療各種臨床適應症的血栓症形成，包括一般外科手術、整形外科手術、神經外科手術、創傷、不穩定型心絞痛和心肌梗塞。然而，在血栓性栓塞症的情況下，與未分級肝素（UFH）相比，皮下注射低分子肝素具有更高的抗凝血效果和生物利用度。由於低分子肝素不會通過胎盤，因此是併發症妊娠最適合的抗凝血劑。低分子肝素（LMWH）的例子包括達肝素和依諾肝素，它們都是抗凝血劑。低分子肝素透過皮下注射給藥。這對於預防性抗凝血劑的選擇具有長期意義，例如，對於接受關節重建手術的整形外科患者，以及對於深層靜脈栓塞症和肺動脈栓塞（DVT/PE）的治療。患者通常不喜歡注射，尤其是自行注射，他們會抱怨注射過程中的疼痛和出血，因此往往更傾向於口服藥物等替代療法。

市場動態

深層靜脈栓塞症（DVT）患者人數不斷增加，因此，低分子肝素（LMWH）的需求也預計會上升。例如，根據美國疾病管制與預防中心（CDC）下屬的國家生育異常和發育障礙中心的數據，以及CDC 2021年7月的報告，目前尚不清楚美國每年究竟有多少人患有深層靜脈栓塞症（DVT）或肺動脈栓塞（PE），但估計可能高達90萬人。據估計，2019年美國有6萬至10萬名公民死於深部靜脈血栓形成/肺栓塞（也稱為靜脈血栓栓塞症，或VTE）。 2017年4月發表於《加拿大醫學會雜誌》的一篇病例報告指出，接受靜脈血栓栓塞症治療（尤其是雌激素）的男變女跨性別者發生深層靜脈栓塞症和肺動脈栓塞）的風險是一般人的20倍。 2019年發表於《血液醫學雜誌》的Meta分析回顧了13項研究，這些研究探討了荷爾蒙療法（包括所用雌激素的類型）對跨性別男性和女性的影響。結果表明，某些配方的荷爾蒙療法會增加VTE的風險，但絕對臨床風險較低。

本報告的主要特點

• 本報告對全球低分子量肝素市場進行了詳細分析，包括市場規模和預測期（2026-2033 年）的複合年成長率，以 2025 年為基準年。
• 此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
• 本文根據以下參數，介紹了全球低分子量肝素市場主要企業的概況：公司概況、產品系列、主要亮點、財務績效和策略。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
• 《全球低分子量肝素市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過分析全球低分子量肝素市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 阻礙因素
  • 市場機遇
• 影響分析
• 流行病學
• 主要進展
• 策略收購
• 低分子肝素相對於普通肝素的優勢
• 低分子肝素和普通肝素的成本效益
• 依諾肝素供不應求及預計補給時間
• 藥物輸送系統
• 監管趨勢
• 贖回方案
• 買進結算模式和白背頻道
• PEST分析

第4章：全球低分子量肝素市場：依藥物分類（2026-2033 年）

• 概述
• 依諾肝素
• 達肝素
• 那屈肝素
• 貝米帕林
• 金扎帕林
• 其他

第5章：全球低分子量肝素市場：依包裝類型分類（2026-2033 年）

• 概述
• 多管瓶
• 預填充式注射器

第6章：全球低分子量肝素市場：依應用領域分類（2026-2033年）

• 概述
• 深層靜脈栓塞症
• 急性冠狀動脈症候群（ACS）
• 肺動脈栓塞
• 心房顫動

第7章：全球低分子量肝素市場：依最終使用者分類（2026-2033 年）

• 概述
• 醫院
• 私人的
• 民眾
• 診所
• 居家醫療

第8章：全球低分子量肝素市場：依地區分類（2026-2033年）

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第9章 競爭情勢

• 熱圖分析
• 公司簡介
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Aspen Pharmacare Holdings
  • Laboratorios Farmaceuticos ROVI SA
  • Changzhou Qianhong Biopharma
  • Intrapharm Laboratories

第10章

• 參考
• 分析方法

Low Molecular Weight Heparin Market is estimated to be valued at USD 5,073.90 Mn in 2026 and is expected to reach USD 8,008.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.

Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from unfractionated heparin (UFH) by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are however, associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin UFH, for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane. Low-molecular-weight heparins (LMWHs), for example, dalteparin, enoxaparin, among others, are anticoagulants. Low molecular weight heparins administration is via subcutaneous injection; this has long-term implications on the choice of anticoagulant for prophylaxis, for example, in orthopedic patients recovering from joint replacement surgery or in the treatment of Deep Vein Thrombosis and Pulmonary Embolism (DVT/PE). Patients often dislike injections, especially self-administered ones, complaining of pain or bleeding with injection, and prefer an oral alternative.

Market Dynamics

Increasing number of people are being affected with Deep Vein Thrombosis (DVT) which will subsequently increase demand for Low Molecular Weight Heparins (LMWH). For instance, according to National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention (CDC), Furthermore, in July 2021, according to Centers for disease control and prevention, the precise number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE) is unknown, although as many as 900,000 people could be affected each year in the United States. Estimates suggest that 60,000-100,000 American citizens in 2019 die of DVT/PE (also called venous thromboembolism, or VTE). A case study published in April 2017 in the Canadian Medical Association Journal noted that the risk of venous thromboembolism (VTE), which includes both DVT and pulmonary embolism (PE), increases 20-fold in male-to-female people using hormone treatment, especially estrogen. A meta-analysis published in 2019 in the Journal of Blood Medicine reviewed 13 studies that looked at the effects of hormone therapy, including which types of estrogen are used, on transgender men and women. It found that even though the risk of VTE increased with certain formulations of hormone therapy, the absolute clinical risk is low.

Key features of the study

• This report provides an in-depth analysis of the global low molecular weight heparin market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global low molecular weight heparin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Inc., LEO Pharma A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, Changzhou Qianhong Biopharma, and Intrapharm Laboratories.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global low molecular weight heparin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global low molecular weight heparin market

Market Segmentation

• By Drug
  • Enoxaparin
  • Dalteparin
  • Nadroparin
  • Bemiparin
  • Tinzaparin
  • Others
• By Packaging
  • Multi-vials
  • Prefilled Syringes
• By Application
  • Deep Vein Thrombosis
  • Acute Coronary Syndrome (ACS)
  • Pulmonary Embolism
  • Atrial Fibrillation
• By End User
  • Hospitals
  • Private
  • Public
  • Clinics
  • Home
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Abbott Laboratories
  • Aspen Pharmacare Holdings
  • Laboratorios Farmaceuticos ROVI SA
  • Changzhou Qianhong Biopharma
  • Intrapharm Laboratories

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug
  • Market Snapshot, By Packaging
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Epidemiology
• Key Developments
• Strategic Acquisitions
• Advantages of LMWH over UFH
• Cost-effectiveness of LMWH vs. UFH
• Shortage of Enoxaparin & Estimated Resupply Dates
• Drug Delivery Systems
• Regulatory Scenario
• Reimbursement Scenario
• Buy-and-bill and White Bagging Channel
• PEST Analysis

4. Global Low Molecular Weight Heparin Market, By Drug, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Enoxaparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Dalteparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Nadroparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Bemiparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Tinzaparin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

5. Global Low Molecular Weight Heparin Market, By Packaging, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Multi-vials
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Prefilled Syringes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

6. Global Low Molecular Weight Heparin Market, By Application, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Deep Vein Thrombosis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Acute Coronary Syndrome (ACS)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Pulmonary Embolism
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Atrial Fibrillation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

7. Global Low Molecular Weight Heparin Market, By End User, 2026 - 2033, (USD Mn)

• Overview
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Hospitals
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Private
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Public
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
• Home
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)

8. Global Low Molecular Weight Heparin Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Packaging, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Key Strategies
  • LEO Pharma A/S
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Sanofi S.A.
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Amphastar Pharmaceuticals Inc.
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Aspen Pharmacare Holdings
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Laboratorios Farmaceuticos ROVI SA
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Changzhou Qianhong Biopharma
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies
  • Intrapharm Laboratories
    • Company Overview
    • Drug Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Key Strategies

10. Section

• References
• Research Methodology
• About Us and Sales Contact